{"downloaded": true, "htmlmade": false, "full": {"id": "30082475", "source": "MED", "pmid": "30082475", "pmcid": "PMC7731903", "fullTextIdList": {"fullTextId": "PMC7731903"}, "doi": "10.1158/1078-0432.ccr-18-0286", "title": "Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.", "authorString": "Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D.", "authorList": {"author": [{"fullName": "Kelly KR", "firstName": "Kevin R", "lastName": "Kelly", "initials": "KR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "USC Norris Comprehensive Cancer Center, Los Angeles, California (previously University of Texas Health Science Center at San Antonio, San Antonio, Texas). kevin.kelly@med.usc.edu."}}}, {"fullName": "Friedberg JW", "firstName": "Jonathan W", "lastName": "Friedberg", "initials": "JW", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Rochester Medical Center, Rochester, New York."}}}, {"fullName": "Park SI", "firstName": "Steven I", "lastName": "Park", "initials": "SI", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Levine Cancer Institute and Carolinas Healthcare System, Charlotte, North Carolina."}}}, {"fullName": "McDonagh K", "firstName": "Kevin", "lastName": "McDonagh", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Vanderbilt University, Nashville, Tennessee (previously University of Kentucky Markey Cancer Center, Lexington, Kentucky)."}}}, {"fullName": "Hayslip J", "firstName": "John", "lastName": "Hayslip", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Kentucky Markey Cancer Center, Lexington, Kentucky."}}}, {"fullName": "Persky D", "firstName": "Daniel", "lastName": "Persky", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Arizona, Tucson, Arizona."}}}, {"fullName": "Ruan J", "firstName": "Jia", "lastName": "Ruan", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Weill Cornell Medical College, New York, New York."}}}, {"fullName": "Puvvada S", "firstName": "Soham", "lastName": "Puvvada", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Arizona, Tucson, Arizona."}}}, {"fullName": "Rosen P", "firstName": "Peter", "lastName": "Rosen", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Providence St Joseph Medical Center, Disney Family Cancer Center, Burbank, California."}}}, {"fullName": "Iyer SP", "firstName": "Swaminathan Padmanabhan", "lastName": "Iyer", "initials": "SP", "authorId": {"@type": "ORCID", "#text": "0000-0002-1646-813X"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Methodist Hospital, Houston, Texas."}}}, {"fullName": "Stefanovic A", "firstName": "Alexandra", "lastName": "Stefanovic", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Miami Miller School of Medicine, Sylvester Cancer Center, Miami, Florida."}}}, {"fullName": "Bernstein SH", "firstName": "Steven H", "lastName": "Bernstein", "initials": "SH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Rochester Medical Center, Rochester, New York."}}}, {"fullName": "Weitman S", "firstName": "Steven", "lastName": "Weitman", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Texas Health Science Center at San Antonio, San Antonio, Texas."}}}, {"fullName": "Karnad A", "firstName": "Anand", "lastName": "Karnad", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Texas Health Science Center at San Antonio, San Antonio, Texas."}}}, {"fullName": "Monohan G", "firstName": "Gregory", "lastName": "Monohan", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Kentucky Markey Cancer Center, Lexington, Kentucky."}}}, {"fullName": "VanderWalde A", "firstName": "Ari", "lastName": "VanderWalde", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Tennessee Health Science Center and West Clinic, Memphis, Tennessee."}}}, {"fullName": "Mena R", "firstName": "Raul", "lastName": "Mena", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Providence St Joseph Medical Center, Disney Family Cancer Center, Burbank, California."}}}, {"fullName": "Schmelz M", "firstName": "Monika", "lastName": "Schmelz", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pathology, College of Medicine, University of Arizona, Tucson, Arizona."}}}, {"fullName": "Spier C", "firstName": "Catherine", "lastName": "Spier", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pathology, College of Medicine, University of Arizona, Tucson, Arizona."}}}, {"fullName": "Groshen S", "firstName": "Susan", "lastName": "Groshen", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "USC Norris Comprehensive Cancer Center, Los Angeles, California (previously University of Texas Health Science Center at San Antonio, San Antonio, Texas)."}}}, {"fullName": "Venkatakrishnan K", "firstName": "Karthik", "lastName": "Venkatakrishnan", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited."}}}, {"fullName": "Zhou X", "firstName": "Xiaofei", "lastName": "Zhou", "initials": "X", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited."}}}, {"fullName": "Sheldon-Waniga E", "firstName": "Emily", "lastName": "Sheldon-Waniga", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Bluebird Bio, Cambridge, Massachusetts (previously Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)."}}}, {"fullName": "Leonard EJ", "firstName": "E Jane", "lastName": "Leonard", "initials": "EJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited."}}}, {"fullName": "Mahadevan D", "firstName": "Daruka", "lastName": "Mahadevan", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Arizona, Tucson, Arizona."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-1646-813X"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "24", "volume": "24", "journalIssueId": "2761195", "dateOfPublication": "2018 Dec", "monthOfPublication": "12", "yearOfPublication": "2018", "printPublicationDate": "2018-12-01", "journal": {"title": "Clinical cancer research : an official journal of the American Association for Cancer Research", "ISOAbbreviation": "Clin Cancer Res", "medlineAbbreviation": "Clin Cancer Res", "NLMid": "9502500", "ISSN": "1078-0432", "ESSN": "1557-3265"}}, "pubYear": "2018", "pageInfo": "6150-6159", "abstractText": "<h4>Purpose</h4>The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended phase II dose (RP2D) of alisertib in combination with rituximab \u00b1 vincristine in patients with relapsed/refractory aggressive B-NHL.<h4>Patients and methods</h4>Patients with relapsed/refractory, diffuse, large, or other aggressive B-NHL received oral alisertib 50 mg b.i.d. days 1 to 7, plus i.v. rituximab 375 mg/m<sup>2</sup> on day 1, for up to eight 21-day cycles (MR). Patients in subsequent cohorts (3 + 3 design) received increasing doses of alisertib (30 mg starting dose; 10 mg increments) b.i.d. days 1 to 7 plus rituximab and vincristine [1.4 mg/m<sup>2</sup> (maximum 2 mg) days 1, 8] for 8 cycles (MRV). Patients benefiting could continue single-agent alisertib beyond 8 cycles. Cell-of-origin and MYC/BCL2 IHC was performed on available archival tissue.<h4>Results</h4>Forty-five patients participated. The alisertib RP2D for MR was 50 mg b.i.d. For MRV (<i>n</i> = 32), the RP2D was determined as 40 mg b.i.d. [1 dose-limiting toxicity (DLT) at 40 mg; 2 DLTs at 50 mg]. Drug-related adverse events were reported in 89% of patients, the most common was neutropenia (47%). Seven patients had complete responses (CR), 7 had partial responses (PRs); 9 of 20 (45%) patients at the MRV RP2D responded (4 CRs, 5 PRs), all with non-germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL).<h4>Conclusions</h4>The combination of alisertib 50 mg b.i.d. plus rituximab or alisertib 40 mg b.i.d. plus rituximab and vincristine was well tolerated and demonstrated activity in non-GCB DLBCL.", "affiliation": "USC Norris Comprehensive Cancer Center, Los Angeles, California (previously University of Texas Health Science Center at San Antonio, San Antonio, Texas). kevin.kelly@med.usc.edu.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Clinical Trial, Phase I", "Journal Article"]}, "grantsList": {"grant": {"grantId": "P30 CA014089", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Lymphoma, B-Cell", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm Metastasis"}, {"majorTopic_YN": "N", "descriptorName": "Disease Progression"}, {"majorTopic_YN": "N", "descriptorName": "Recurrence"}, {"majorTopic_YN": "N", "descriptorName": "Vincristine", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Azepines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Pyrimidines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Drug Monitoring"}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm Staging"}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Retreatment"}, {"majorTopic_YN": "N", "descriptorName": "Maximum Tolerated Dose"}, {"majorTopic_YN": "N", "descriptorName": "Drug Resistance, Neoplasm"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Molecular Targeted Therapy"}, {"majorTopic_YN": "N", "descriptorName": "Aurora Kinase A", "meshQualifierList": {"meshQualifier": {"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Rituximab", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}]}, "chemicalList": {"chemical": [{"name": "Pyrimidines", "registryNumber": "0"}, {"name": "Azepines", "registryNumber": "0"}, {"name": "MLN 8237", "registryNumber": "0"}, {"name": "Aurora Kinase A", "registryNumber": "EC 2.7.11.1"}, {"name": "Rituximab", "registryNumber": "4F4X42SYQ6"}, {"name": "Vincristine", "registryNumber": "5J49Q6B70F"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/1078-0432.CCR-18-0286"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7731903"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7731903?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/1078-0432.ccr-18-0286"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "7", "hasData": "Y", "hasReferences": "N", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS1622553", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-12-18", "dateOfCreation": "2018-08-08", "firstIndexDate": "2018-08-08", "fullTextReceivedDate": "2020-12-14", "dateOfRevision": "2020-12-12", "electronicPublicationDate": "2018-08-06", "firstPublicationDate": "2018-08-06"}, "abstract": "<h4>Purpose</h4>The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended phase II dose (RP2D) of alisertib in combination with rituximab \u00b1 vincristine in patients with relapsed/refractory aggressive B-NHL.<h4>Patients and methods</h4>Patients with relapsed/refractory, diffuse, large, or other aggressive B-NHL received oral alisertib 50 mg b.i.d. days 1 to 7, plus i.v. rituximab 375 mg/m<sup>2</sup> on day 1, for up to eight 21-day cycles (MR). Patients in subsequent cohorts (3 + 3 design) received increasing doses of alisertib (30 mg starting dose; 10 mg increments) b.i.d. days 1 to 7 plus rituximab and vincristine [1.4 mg/m<sup>2</sup> (maximum 2 mg) days 1, 8] for 8 cycles (MRV). Patients benefiting could continue single-agent alisertib beyond 8 cycles. Cell-of-origin and MYC/BCL2 IHC was performed on available archival tissue.<h4>Results</h4>Forty-five patients participated. The alisertib RP2D for MR was 50 mg b.i.d. For MRV (<i>n</i> = 32), the RP2D was determined as 40 mg b.i.d. [1 dose-limiting toxicity (DLT) at 40 mg; 2 DLTs at 50 mg]. Drug-related adverse events were reported in 89% of patients, the most common was neutropenia (47%). Seven patients had complete responses (CR), 7 had partial responses (PRs); 9 of 20 (45%) patients at the MRV RP2D responded (4 CRs, 5 PRs), all with non-germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL).<h4>Conclusions</h4>The combination of alisertib 50 mg b.i.d. plus rituximab or alisertib 40 mg b.i.d. plus rituximab and vincristine was well tolerated and demonstrated activity in non-GCB DLBCL.", "journaltitle": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authorinfo": ["Kelly KR", "Friedberg JW", "Park SI", "McDonagh K", "Hayslip J", "Persky D", "Ruan J", "Puvvada S", "Rosen P", "Iyer SP", "Stefanovic A", "Bernstein SH", "Weitman S", "Karnad A", "Monohan G", "VanderWalde A", "Mena R", "Schmelz M", "Spier C", "Groshen S", "Venkatakrishnan K", "Zhou X", "Sheldon-Waniga E", "Leonard EJ", "Mahadevan D"], "title": "Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma."}